Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C

[Guest guest]

Hepatology. 2008 May 9;48(2):407-417. [Epub ahead of print]

Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients

with genotype 1 chronic hepatitis C.

Zeuzem S, Yoshida EM, Benhamou Y, Pianko S, Bain VG, Shouval D, Flisiak R, Rehak

V, Grigorescu M, Kaita K, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison

JG.

J.W. Goethe-University Hospital, furt, Germany.

The efficacy and safety of albinterferon alfa-2b (alb-IFN), a novel recombinant

protein consisting of interferon alfa-2b genetically fused to human albumin, was

evaluated in a phase 2b, open-label study of patients with genotype 1, chronic

hepatitis C. In all, 458 IFN-alfa treatment-naïve patients were randomized to

48-week treatment with peginterferon alfa (PEG-IFNalpha)-2a 180 mug one time per

week (qwk), or alb-IFN 900 or 1,200 mug once every two weeks (q2wk), or 1,200

mug once every four weeks (q4wk), administered subcutaneously, plus weight-based

oral ribavirin 1,000 or 1,200 mg/day. Hepatitis C virus RNA was measured by

real-time polymerase chain reaction (limit of detection: 10 IU/mL). The primary

efficacy endpoint was sustained virologic response (hepatitis C virus RNA

[Guest guest]

Hepatology. 2008 May 9;48(2):407-417. [Epub ahead of print]

Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients

with genotype 1 chronic hepatitis C.

Zeuzem S, Yoshida EM, Benhamou Y, Pianko S, Bain VG, Shouval D, Flisiak R, Rehak

V, Grigorescu M, Kaita K, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison

JG.

J.W. Goethe-University Hospital, furt, Germany.

The efficacy and safety of albinterferon alfa-2b (alb-IFN), a novel recombinant

protein consisting of interferon alfa-2b genetically fused to human albumin, was

evaluated in a phase 2b, open-label study of patients with genotype 1, chronic

hepatitis C. In all, 458 IFN-alfa treatment-naïve patients were randomized to

48-week treatment with peginterferon alfa (PEG-IFNalpha)-2a 180 mug one time per

week (qwk), or alb-IFN 900 or 1,200 mug once every two weeks (q2wk), or 1,200

mug once every four weeks (q4wk), administered subcutaneously, plus weight-based

oral ribavirin 1,000 or 1,200 mg/day. Hepatitis C virus RNA was measured by

real-time polymerase chain reaction (limit of detection: 10 IU/mL). The primary

efficacy endpoint was sustained virologic response (hepatitis C virus RNA